Timing matters: when to first assess symptoms in UC treatment?
NCT ID NCT06998693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study from Xijing Hospital looked at 180 adults with mild-to-moderate ulcerative colitis starting 5-ASA therapy. Researchers compared checking symptoms at 4, 8, or 12 weeks to see which timing best predicted treatment success at 48 weeks. The goal was to help doctors personalize treatment decisions by identifying early responders and non-responders.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 5-ASA (mesalazine)
- What this could lead to
- If successful, this study could help doctors know when to first check symptoms to better tailor 5-ASA treatment for ulcerative colitis patients.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't prove a new therapy works. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710032, China